These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 29413286)
1. Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis. Barney CL; Scoville N; Allan E; Ayan A; DiCostanzo D; Haglund KE; Grecula J; Williams T; Xu-Welliver M; Otterson GA; Bazan JG Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):748-755. PubMed ID: 29413286 [TBL] [Abstract][Full Text] [Related]
2. Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer. Deek MP; Benenati B; Kim S; Chen T; Ahmed I; Zou W; Aisner J; Jabbour SK Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):147-154. PubMed ID: 26700708 [TBL] [Abstract][Full Text] [Related]
3. Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal. Bazan JG; Luxton G; Mok EC; Koong AC; Chang DT Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):700-6. PubMed ID: 22414279 [TBL] [Abstract][Full Text] [Related]
4. Increasing Radiation Dose to the Thoracic Marrow Is Associated With Acute Hematologic Toxicities in Patients Receiving Chemoradiation for Esophageal Cancer. Fabian D; Ayan A; DiCostanzo D; Barney CL; Aljabban J; Diaz DA; Miller ED; Wuthrick E; Williams TM; Bazan JG Front Oncol; 2019; 9():147. PubMed ID: 30931257 [No Abstract] [Full Text] [Related]
5. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy. Bazan JG; Luxton G; Kozak MM; Anderson EM; Hancock SL; Kapp DS; Kidd EA; Koong AC; Chang DT Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):983-91. PubMed ID: 24161422 [TBL] [Abstract][Full Text] [Related]
6. Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal. Cheng JC; Bazan JG; Wu JK; Koong AC; Chang DT Pract Radiat Oncol; 2014; 4(3):198-206. PubMed ID: 24766688 [TBL] [Abstract][Full Text] [Related]
7. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer. Tang C; Lee MS; Gomez D; Levy LB; Zhuang Y; Lu C; Liao Z; Komaki R Am J Clin Oncol; 2017 Dec; 40(6):625-630. PubMed ID: 26165417 [TBL] [Abstract][Full Text] [Related]
8. Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation. Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U Med Oncol; 2016 Dec; 33(12):137. PubMed ID: 27815805 [TBL] [Abstract][Full Text] [Related]
9. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy. Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902 [TBL] [Abstract][Full Text] [Related]
10. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. Salama JK; Stinchcombe TE; Gu L; Wang X; Morano K; Bogart JA; Crawford JC; Socinski MA; Blackstock AW; Vokes EE; Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e269-74. PubMed ID: 21477940 [TBL] [Abstract][Full Text] [Related]
11. The Role of Thoracic Vertebral Body Dosimetry in Minimizing Acute Hematologic Toxicities of Patients With Non-Small Cell Lung Cancer Receiving Lung Radiation Therapy and Immunotherapy. Ma J; Li Y; Yu H; Zhang J; Zhang Y; Verma V; Chen H; Qin X; Zhai X; Shang S; Shangguan J; Wang R; Tian C; Wang F; Yu J; Chen D Int J Radiat Oncol Biol Phys; 2024 May; 119(1):78-89. PubMed ID: 38040058 [TBL] [Abstract][Full Text] [Related]
12. Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy. Newman NB; Sidhu MK; Baby R; Moss RA; Nissenblatt MJ; Chen T; Lu SE; Jabbour SK Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1052-60. PubMed ID: 27026312 [TBL] [Abstract][Full Text] [Related]
13. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China. Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745 [TBL] [Abstract][Full Text] [Related]
14. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Palma DA; Senan S; Tsujino K; Barriger RB; Rengan R; Moreno M; Bradley JD; Kim TH; Ramella S; Marks LB; De Petris L; Stitt L; Rodrigues G Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):444-50. PubMed ID: 22682812 [TBL] [Abstract][Full Text] [Related]
15. Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters. Katsui K; Ogata T; Watanabe K; Katayama N; Kuroda M; Kiura K; Hiraki T; Maeda Y; Toyooka S; Kanazawa S Cancer Med; 2020 Jul; 9(13):4540-4549. PubMed ID: 32364685 [TBL] [Abstract][Full Text] [Related]
16. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342 [TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Wang L; Wu S; Ou G; Bi N; Li W; Ren H; Cao J; Liang J; Li J; Zhou Z; Lv J; Zhang X Lung Cancer; 2012 Jul; 77(1):89-96. PubMed ID: 22418243 [TBL] [Abstract][Full Text] [Related]
18. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters. Zhou Y; Yan T; Zhou X; Cao P; Luo C; Zhou L; Xu Y; Liu Y; Xue J; Wang J; Wang Y; Lu Y; Liang B; Gong Y Strahlenther Onkol; 2020 Jun; 196(6):505-514. PubMed ID: 31828393 [TBL] [Abstract][Full Text] [Related]
19. Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer. Jiang N; Chen XC; Zhao Y Support Care Cancer; 2013 Mar; 21(3):785-91. PubMed ID: 22936496 [TBL] [Abstract][Full Text] [Related]
20. Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy. Kwint M; Uyterlinde W; Nijkamp J; Chen C; de Bois J; Sonke JJ; van den Heuvel M; Knegjens J; van Herk M; Belderbos J Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):e223-8. PubMed ID: 22560551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]